Compugen's Upcoming Participation in a Healthcare Conference
Compugen Ltd. (Nasdaq: CGEN), a prominent player in the field of cancer immunotherapy, recently announced that its management team will engage in a notable fireside chat at the upcoming Stifel 2025 Healthcare Conference. This prestigious event taking place in New York City aims to gather leaders in the healthcare sector to discuss innovative cancer treatment methods.
Details of the Event
The fireside chat is scheduled for a convenient afternoon slot, with it taking place on a Tuesday between 3:20 and 3:50 PM ET. During this time, Compugen's management will delve into the latest advancements their team has achieved in harnessing AI and ML for drug target discovery in the oncology space.
Webcast Availability
A live webcast of the session will be made accessible through the Investor Relations section of Compugen's official website. For those who cannot attend the live session, a replay will be made available shortly after the event, allowing investors and interested parties to catch up on the significant insights shared.
About Compugen
Compugen specializes in the field of therapeutic discovery and development, focusing on cutting-edge cancer treatments powered by artificial intelligence and machine learning. Their unique computational discovery platform, Unigen™, serves as a cornerstone for identifying promising drug targets and biological pathways that can lead to breakthroughs in cancer immunotherapies.
Innovative Product Pipeline
Compugen's innovative pipeline includes two proprietary product candidates currently in Phase 1 clinical trials. The first is COM701, an anticipated first-in-class anti-PVRIG antibody, while the second, COM902, targets TIGIT with the objective of becoming the best in its category for treating solid tumors. In addition, Rilvegostomig, a PD-1/TIGIT bispecific antibody, is under development in a Phase 3 trial by AstraZeneca, highlighting the potential collaboration and trust that the industry places in Compugen’s research.
Strategic Collaborations and Research Efforts
Another significant element of Compugen's portfolio is GS-0321, formerly known as COM503, which is a high-affinity anti-IL-18 binding protein antibody and currently in Phase 1 development under license to Gilead. Compugen also hasn't overlooked the importance of early-stage immuno-oncology programs focusing on novel mechanisms to stimulate the immune system to combat cancer, further solidifying its role in oncology research and therapy development.
Headquarters and Investor Relations
Compugen is based in Israel, with a dedicated office in San Francisco, CA, fostering close ties to major markets. Investors can find additional information on Compugen's financial performance and product development by reaching out to their Investor Relations department. Yvonne Naughton, Ph.D., the Vice President and Head of Investor Relations and Corporate Communications, is available for inquiries, ensuring that stakeholders have access to necessary information pertaining to the company's future prospects.
Frequently Asked Questions
What is Compugen Ltd. primarily focused on?
Compugen Ltd. focuses on developing cancer immunotherapies using advanced AI and ML technologies to discover novel drug targets.
When will Compugen participate in the Stifel Healthcare Conference?
Compugen's management will participate in the conference on a Tuesday afternoon between 3:20 and 3:50 PM ET.
Where can I watch the Compugen fireside chat?
The fireside chat will be available via a webcast on Compugen's Investor Relations website.
What are some key product candidates of Compugen?
Compugen's key candidates include COM701 and COM902, both undergoing clinical trials for treating various types of solid tumors.
How can I contact Compugen's Investor Relations?
For inquiries, you can reach out to Yvonne Naughton, Ph.D., the Vice President of Investor Relations, who is open to answering questions regarding the company's developments.
